Research programme: siRNA therapeutics - Celixir
Alternative Names: CLXR-005; siRNA molecules - CelixirLatest Information Update: 28 Jun 2023
At a glance
- Originator Celixir
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action RNA interference; STAT6 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Colorectal cancer
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Breast-cancer in United Kingdom (Parenteral)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Colorectal-cancer in United Kingdom (Parenteral)
- 14 May 2019 Preclinical trials in Breast cancer in United Kingdom (parenteral)